BioInvent International AB (publ) announces the appointment of Marie Moores as Chief Operating Officer. Marie Moores joins the company on February 1, 2022, and she will be involved in all operational aspects including quality assurance as well as commercial strategy planning such as further developing the target product profiles for BioInvent's drug candidates. Marie Moores has over 25 years' experience of transforming international organizations, with expertise in regulatory affairs and building businesses focusing on drug development.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
29.95 SEK | +1.53% | +17.53% | +55.59% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.59% | 181M | |
+8.64% | 114B | |
+10.53% | 104B | |
-12.61% | 22.41B | |
-0.52% | 22.28B | |
-5.80% | 19.07B | |
-37.36% | 18B | |
-5.29% | 17.89B | |
+7.20% | 14.28B | |
+36.58% | 12.55B |
- Stock Market
- Equities
- BINV Stock
- News BioInvent International AB
- BioInvent International AB Appoints Marie Moores as Chief Operating Officer, on February 1, 2022